Format

Send to

Choose Destination

See 1 citation found by title matching your search:

Clin Rehabil. 2010 Jun;24(6):523-32. doi: 10.1177/0269215509360646. Epub 2010 May 18.

Do metronomes improve the quality of life in people with Parkinson's disease? A pragmatic, single-blind, randomized cross-over trial.

Author information

1
Peninsula Technology Assessment Group, Peninsula Medical School, University of Exeter, UK. julian.elston@nhs.net

Abstract

OBJECTIVE:

To evaluate the effect of acoustic cueing using metronomes on the quality of life of people with moderate to severe Parkinson's disease.

STUDY DESIGN:

Pragmatic, single-blind, randomized cross-over trial.

PARTICIPANTS:

Forty-two people aged 50-85 years, in Hoehn and Yahr stage II-IV and on stable medication. Eight were lost to follow-up.

INTERVENTION:

Participants were randomized using concealed allocation to either an early group (n = 21) to receive an electronic metronome without therapy but limited support (5-10 minutes instruction and on-demand telephone assistance) for four weeks, or a late group (n = 21) to receive the same intervention at 10 weeks. In both groups the beat frequency was initially set to be comfortable for walking.

OUTCOMES MEASURES:

Primary and secondary outcomes were measured at baseline, 4, 10 and 14 weeks using the Parkinson's Disease Questionnaire 39 (PDQ-39), the Short Form 36 version 2 (SF-36 version 2) and a falls diary.

RESULTS:

There were positive effects in six domains of the SF-36 version 2 and eight domains of the PDQ-39, although only one mean difference was clinically important: the role limitation (emotional) domain of SF-36 version 2 (a mean difference of 3.77, 95% confidence interval (CI), -2.68 to 10.22), a secondary outcome. None of these changes were statistically significant. There were no statistically significant differences in falls rates over the study period. Ten participants (24%) wanted to continue with their metronomes at the end of the study.

CONCLUSION:

To demonstrate metronomes are beneficial on the role limitation domain of the SF-36 version 2 in people with moderate to severe Parkinson's disease a sample size of 600 would be required.

PMID:
20483888
DOI:
10.1177/0269215509360646
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center